According to a judicial panel, lawsuits involving Takeda’s blockbuster diabetes drug Actos (pioglitazone) will be centralized before one judge in Louisiana federal court. The complaints allege that patients who use Actos are at an increased risk of developing bladder cancer, and that Takeda knowingly withheld information about this risk and failed to provide adequate warnings. To date, dozens of Actos bladder cancer lawsuits have been filed in courts throughout the country, and many more are expected in the near future.
Actos Bladder Cancer Lawsuit Update April 8, 2014: In the first U.S. trial of its kind, Takeda Pharmaceuticals and Eli Lilly were ordered to pay a total of $9 billion in punitive damages after a jury agreed that the companies failed to warn the public and medical communities about the bladder cancer risk associated with their controversial type 2 diabetes drug Actos (pioglitazone). The lawsuit claimed that Takeda and Lilly downplayed or ignored concerns about Actos’ link to bladder cancer, and mislead health authorities in order to protect profits. Click here to learn more.
Free Actos Bladder Cancer Lawsuit Evaluation: If you or a loved one has developed bladder cancer after taking Actos, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against Takeda Pharmaceuticals and we can help.
What’s the problem?
December 31, 2011 – The federal Judicial Panel on Multidistrict Litigation (MDL) ordered that the Actos bladder cancer legal claims be centralized and overseen by U.S. District Judge Rebecca Doherty in the Western District of Louisiana, Lafayette. Doherty will handle all pretrial actions, including evidence gathering and discovery.
“Centralization in the Western District of Louisiana will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation,” the panel ruled yesterday. It will also allow “the panel to assign the litigation to an experienced judge who sits in a district in which no other multidistrict litigation is pending.”
Takeda stated in a September filing that at least 54 Actos bladder cancer complaints had been filed up to that point. Since then, dozens more lawsuits have been added in federal courthouses around the country.
In June, health regulators from the U.S. Food & Drug Administration (FDA) found that an analysis of a Takeda-sponsored study showed that some Actos users faced an increased risk of developing potentially-fatal cases of bladder cancer. The federal lawsuits were all filed in June or later, and consolidated in In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).
Actos was banned in Germany and France earlier this year after independent investigations linked the drug to an increased risk of bladder cancer.
Do You Have an Actos Bladder Cancer Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Actos lawsuits. We are handling individual litigation nationwide and currently accepting new bladder cancer cases in all 50 states.
Free Actos Bladder Cancer Lawsuit Evaluation: If you or a loved one has developed bladder cancer after taking Actos, you should contact our law firm immediately. You may be entitled to compensation by filing an Actos bladder cancer suit and we can help.